Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive factors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcinosarcomas may benefit more from adjuvant CT.Aims: We aimed to define the prognostic and predictive factors associated with treatment options in ovarian (OCS) and uterine carcinosarcoma (UCS).Study Design: Retrospective cross-sectional studyMethods: We retrospectively reviewed the medical records of patients with ovarian and uterine carcinosarcoma from 2000 to 2013, and 127 women were included in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey between 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data obtained from well-kept medical records were included in this study. Stage IV tumours were excluded. The patient records were retrospectively reviewed. Data from 104 patients were evaluated for this study.Results: Age (>= 70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic +/- para aortic lymph node dissection did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p<0.01). The median OS was significantly longer in stage I-II patients than stage III patients (p=0.03). Adjuvant treatment improved OS (p=0.013). Adjuvant radiotherapy tended to increase the median OS (p=0.075). However, this tendency was observed in UCS (p=0.08) rather than OCS (p=0.6). Adjuvant chemotherapy had no effect on OS (p=0.15). Adjuvant radiotherapy significantly prolonged the median OS in patients with endometrioid component (p=0.034). A serous/clear cell component was a negative prognostic factor (p=0.035). Patients with serous/clear cell histology for whom adjuvant chemotherapy was applied had significantly longer OS (p=0.019), and there was no beneficial effect of adjuvant radiotherapy (p=0.4). Adjuvant chemotherapy was effective in heterologous tumours (p=0.026). In multivariate analysis, the stage and chemotherapy were prognostic factors for all patients. Age was an independent prognostic factor for UCS. However, serous/clear cell histology and radiotherapy tended to be significant prognostic factors.Conclusion: The primary location, the histological type of sarcomatous and the epithelial component may be predictive factors for the efficacy of chemotherapy or radiotherapy in UCS and OCS

Anatolian Society of Medical Oncology)

OBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival

multicenter study from Turkey

Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a secondor third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included.Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (p(PFS)=0.22 and p(OS)=0.85).Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib.C1 [Hacioglu, Muhammet Bekir; Kostek, Osman; Erdogan, Bulent; Cicin, Irfan] Trakya Univ, Dept Med Oncol, Med Fac, Edirne, Turkey.[Karabulut, Senem; Tastekin, Didem] Istanbul Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey.[Goksu, Sema Sezgin] Akdeniz Univ, Med Fac, Dept Med Oncol, Antalya, Turkey.[Alandag, Celal] Karadeniz Tech Univ, Med Fac, Dept Med Oncol, Trabzon, Turkey.[Akagunduz, Baran] Dokuz Eylul Univ, Med Fac, Dept Med Oncol, Izmir, Turkey.[Bilgetekin, Irem] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Dept Med Oncol, Ankara, Turkey.[Caner, Burcu; Sahin, Ahmet Bilgehan] Uludag Univ, Med Fac, Dept Med Oncol, Bursa, Turkey.[Yildiz, Birol] Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkey.[Kose, Fatih] Baskent Univ, Adana Med Fac, Dept Med Oncol, Adana, Turkey.[Kaplan, Muhammet Ali] Dicle Univ, Med Fac, Dept Med Oncol, Diyarbakir, Turkey.[Gulmez, Ahmet] Inonu Univ, Med Fac, Dept Med Oncol, Malatya, Turkey.[Dogan, Ender] Erciyes Univ, Med Fac, Dept Med Oncol, Kayseri, Turkey.[Kilickap, Saadettin] Hacettepe Univ, Med Fac, Dept Med Oncol, Ankara, Turkey.[Guven, Deniz Can; Gurbuz, Mustafa] Ankara Univ, Med Fac, Dept Med Oncol, Ankara, Turkey.[Ergun, Yakup] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey.[Karaagac, Mustafa] Necmettin Erbakan Univ, Med Fac, Dept Med Oncol, Konya, Turkey.[Demiray, Atike Gokcen] Pamukkale Univ, Med Fac, Dept Med Oncol, Denizli, Turkey.[Turker, Sema] DiskapiYildir Beyazit Training & Res Hosp, Dept Med Oncol, Ankara, Turkey.[Sakalar, Teoman] Sakarya Univ Training & Res Hosp, Dept Med Oncol, Aksaray, Turkey.[Ozkul, Ozlem] Sakarya Univ Training & Res Hosp, Dept Med Oncol, Sakarya, Turkey.[Telli, Tugba Akin] Marmara Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey.[Sahin, Suleyman] Van Training & Res Hosp, Dept Med Oncol, Van, Turkey.[Bilici, Ahmet] Medipol Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey

Evaluation of trace element contents of some herbal plants and spices retailed in Kayseri, Turkey

The trace element contents of seven kinds of herbal plants and spice samples retailed in local markets in Kayseri-Turkey were determined by flame atomic absorption spectrometry after digestion with HNO3/H2O2 mixture. The concentration ranges for the studied elements were found as 6.0-15.2, 0-32.2, 80.0-324.8, 8.1-386.3, and 13.1-36.2 mu g/g for copper, nickel, iron, manganese, and zinc, respectively. The levels of cobalt, lead, and chromium ions in all the investigated samples were found to be below the detection limit of flame atomic absorption spectrometry. The results found in the present work were compared with values in the literature

Effect of preoperative single-dose corticosteroid administration on postoperative morbidity following esophagectomy.

Eight clinical trials involving the administration of preoperative i.v. methylprednisolone have been undertaken in order to decrease the considerable inflammatory response to esophageal resection, in an effort to decrease the supposedly associated morbidity and mortalityComparative StudyJournal ArticleMeta-AnalysisReviewSCOPUS: ar.jinfo:eu-repo/semantics/publishe